The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Mortality and cardiovascular and respiratory morbidity in individuals with impaired FEV1 (PURE): an international, community-based cohort study
Open accessAbstract
Background The associations between the extent of forced expiratory volume in 1 s (FEV 1 ) impairment and mortality, incident cardiovascular disease, and respiratory hospitalisations are unclear, and how these associations might vary across populations is unknown. Methods In this international, community-based cohort study, we prospectively enrolled adults aged 35–70 years who had no intention of moving residences for 4 years from rural and urban communities across 17 countries. A portable spirometer was used to assess FEV 1 . FEV 1 values were standardised within countries for height, age, and sex, and expressed as a percentage of the country-specific predicted FEV 1 value (FEV 1 %). FEV 1 % was categorised as no impairment (FEV 1 % ≥0 SD from country-specific mean), mild impairment (FEV 1 % <0 SD to −1 SD), moderate impairment (FEV 1 % <–1 SD to −2 SDs), and severe impairment (FEV 1 % <–2 SDs [ie, clinically abnormal range]). Follow-up was done every 3 years to collect information on mortality, cardiovascular disease outcomes (including myocardial infarction, stroke, sudden death, or congestive heart failure), and respiratory hospitalisations (from chronic obstructive pulmonary disease, asthma, pneumonia, tuberculosis, or other pulmonary conditions). Fully adjusted hazard ratios (HRs) were calculated by multilevel Cox regression. Findings Among 126 359 adults with acceptable spirometry data available, during a median 7·8 years (IQR 5·6–9·5) of follow-up, 5488 (4·3%) deaths, 5734 (4·5%) cardiovascular disease events, and 1948 (1·5%) respiratory hospitalisation events occurred. Relative to the no impairment group, mild to severe FEV 1 % impairments were associated with graded increases in mortality (HR 1·27 [95% CI 1·18–1·36] for mild, 1·74 [1·60–1·90] for moderate, and 2·54 [2·26–2·86] for severe impairment), cardiovascular disease (1·18 [1·10–1·26], 1·39 [1·28–1·51], 2·02 [1·75–2·32]), and respiratory hospitalisation (1·39 [1·24–1·56], 2·02 [1·75–2·32], 2·97 [2·45–3·60]), and this pattern persisted in subgroup analyses considering country income level and various baseline risk factors. Population-attributable risk for mortality (adjusted for age, sex, and country income) from mildly to moderately reduced FEV 1 % (24·7% [22·2–27·2]) was larger than that from severely reduced FEV 1 % (3·7% [2·1–5·2]) and from tobacco use (19·7% [17·2–22·3]), previous cardiovascular disease (5·5% [4·5–6·5]), and hypertension (17·1% [14·6–19·6]). Population-attributable risk for cardiovascular disease from mildly to moderately reduced FEV 1 was 17·3% (14·8–19·7), second only to the contribution of hypertension (30·1% [27·6–32·5]). Interpretation FEV 1 is an independent and generalisable predictor of mortality, cardiovascular disease, and respiratory hospitalisation, even across the clinically normal range (mild to moderate impairment). Funding Population Health Research Institute, the Canadian Institutes of Health Research, Heart and Stroke Foundation of Ontario, Ontario Ministry of Health and Long-Term Care, AstraZeneca, Sanofi-Aventis, Boehringer Ingelheim, Servier, and GlaxoSmithKline, Novartis, and King Pharma. Additional funders are listed in the appendix.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Environment and Disease: Association or Causation?
Hill, A. B. (1965) · Proceedings of the Royal Society of Medicine · doi:10.1177/003591576505800503 · Cited by 6,974
Interpretative strategies for lung function tests
Pellegrino, R., Viegi, G., Brusasco, V., Crapo, R. O., Burgos, F., Casaburi, R., Coates, A., van der Grinten, C. P. M., Gustafsson, P., Hankinson, J., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00035205 · Cited by 5,945
A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction.
Stampfer, M. J., Sacks, F. M., Salvini, S., Willett, W. C., & Hennekens, C. H. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108083250601 · Cited by 1,163
Mortality in COPD: role of comorbidities
Sin, D. D., Anthonisen, N. R., Soriano, J. B., & Agusti, A. G. (2006) · European Respiratory Journal · doi:10.1183/09031936.00133805 · Cited by 1,052
Cited by
Heterogeneous aging across multiple organ systems and prediction of chronic disease and mortality
Tian, Y. E., Cropley, V., Maier, A. B., Lautenschlager, N. T., Breakspear, M., & Zalesky, A. (2023) · Nature Medicine · doi:10.1038/s41591-023-02296-6 · Cited by 618
Improving lung health in low-income and middle-income countries: from challenges to solutions
Meghji, J., Mortimer, K., Agusti, A., Allwood, B. W., Asher, I., Bateman, E. D., Bissell, K., Bolton, C. E., Bush, A., Celli, B., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00458-x · Cited by 470
Goals of COPD treatment: Focus on symptoms and exacerbations
Vogelmeier, C. F., Román-Rodríguez, M., Singh, D., Han, M. K., Rodríguez-Roisin, R., & Ferguson, G. T. (2020) · Respiratory Medicine · doi:10.1016/j.rmed.2020.105938 · Cited by 371
Bhakta, N. R., Bime, C., Kaminsky, D. A., McCormack, M. C., Thakur, N., Stanojevic, S., Baugh, A. D., Braun, L., Lovinsky-Desir, S., Adamson, R., et al. (2023) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202302-0310st · Cited by 297
Post-Tuberculosis Lung Disease: Clinical Review of an Under-Recognised Global Challenge
Allwood, B. W., Byrne, A., Meghji, J., Rachow, A., van der Zalm, M. M., & Schoch, O. D. (2021) · Respiration · doi:10.1159/000512531 · Cited by 277
Metadata
- Authors
- Duong, M., Islam, S., Rangarajan, S., Leong, D., Kurmi, O., Teo, K., Killian, K., Dagenais, G., Lear, S., Wielgosz, A., Nair, S., Mohan, V., Mony, P., Gupta, R., Kumar, R., Rahman, O., Yusoff, K., du Plessis, J. L., Igumbor, E. U., Chifamba, J., Li, W., Lu, Y., Zhi, F., Yan, R., Iqbal, R., Ismail, N., Zatonska, K., Karsidag, K., Rosengren, A., Bahonar, A., Yusufali, A., Lamelas, P. M., Avezum, A., Lopez-Jaramillo, P., Lanas, F., O'Byrne, P. M., & Yusuf, S.
- Venue
- The Lancet Global Health
- Publisher
- Elsevier BV
- Published
- 2019-05
- Volume
- 7
- Issue
- 5
- Pages
- e613-e623
- ISSN
- 2214-109X (ISSN-L)
- OpenAlex
- W2938704617
- Cited by
- 208
- References
- 4
- FWCI
- 13.01
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mortality and cardiovascular and respiratory morbidity in individuals with impaired FEV1 (PURE): an international, community-based cohort study. https://app.cochat.ai/papers/10.1016/s2214-109x(19)30070-1
- The paper
- Duong, M., Islam, S., Rangarajan, S., Leong, D., Kurmi, O., Teo, K., Killian, K., Dagenais, G., Lear, S., Wielgosz, A., Nair, S., Mohan, V., Mony, P., Gupta, R., Kumar, R., Rahman, O., Yusoff, K., du Plessis, J. L., Igumbor, E. U., . . . Yusuf, S. (2019). Mortality and cardiovascular and respiratory morbidity in individuals with impaired FEV1 (PURE): an international, community-based cohort study. The Lancet Global Health. https://doi.org/10.1016/s2214-109x(19)30070-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.